Drug intelligence / Profile preview

ES-1601

Development stage: Unknown
Lead developer: Eusol Biotech
Modality: Recombinant Proteins and Enzymes
Administration: Intralesional

Overview

ES-1601 (also known as ES135) is a recombinant human acidic fibroblast growth factor (rhFGF1) consisting of a 135-amino acid protein sequence. Developed by Eusol Biotech, it is primarily investigated for the treatment of spinal cord injury (SCI). The drug acts as a neurotrophic factor, promoting nerve regeneration, angiogenesis, and functional recovery by binding to and activating fibroblast growth factor receptors (FGFRs). ES-1601 has completed a Phase 3 pivotal clinical trial in Taiwan involving multiple medical centers and has received compassionate use approval for patients with spinal cord injuries.

Other names: rhFGF1rhFGF-1rhFGF 1recombinant human acidic fibroblast growth factoracidic fibroblast growth factor

Targets

FGFR3 (Fibroblast growth factor receptor 3)

Beyond the preview

Go deeper on ES-1601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ES-1601.

Explore the full profile